Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Oct;32(4):483–488. doi: 10.1111/j.1365-2125.1991.tb03935.x

Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

C de Mey 1, D Enterling 1, I Meineke 1, S Yeulet 1
PMCID: PMC1368610  PMID: 1683559

Abstract

1. Ropinirole, SK&F 101468 has been characterized preclinically as a specific dopamine D2-receptor agonist. Nine male healthy subjects were investigated for the effects on supine and erect heart rate and blood pressure, catecholamines and prolactin, of a single dose of 800 micrograms ropinirole preceded by a single dose of 20 mg domperidone or domperidone-placebo, and those of a single dose of domperidone followed by ropinirole-placebo. 2. Single doses of 800 micrograms ropinirole did not cause clinically significant changes in supine resting heart rate and blood pressure. However, they caused postural faintness on 3 min immobile upright standing on 10/26 occasions. 3. Pretreatment with 20 mg domperidone 1 h before administration of ropinirole prevented the postural symptoms in all but one subject. It did not alter ropinirole's plasma pharmacokinetics. 4. Ropinirole did not alter supine or standing catecholamine concentrations. 5. Domperidone increased the plasma concentrations of prolactin whereas ropinirole administered alone reduced them. A single dose of 800 micrograms ropinirole did not attenuate the prolactin increase induced by a single dose of 20 mg domperidone administered 1 h earlier.

Full text

PDF
488

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acton G., Broom C. A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1989 Oct;28(4):435–441. doi: 10.1111/j.1365-2125.1989.tb03524.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clark B. J., Scholtysik G., Flückiger E. Cardiovascular actions of bromocriptine. Acta Endocrinol Suppl (Copenh) 1978;216:75–81. [PubMed] [Google Scholar]
  3. Clemens J. A., Shaar C. J., Smalstig E. B., Bach N. J., Kornfeld E. C. Inhibition of prolactin secretion by ergolines. Endocrinology. 1974 Apr;94(4):1171–1176. doi: 10.1210/endo-94-4-1171. [DOI] [PubMed] [Google Scholar]
  4. Folkow B., Di Bona G. F., Hjemdahl P., Torén P. H., Wallin B. G. Measurements of plasma norepinephrine concentrations in human primary hypertension. A word of caution on their applicability for assessing neurogenic contributions. Hypertension. 1983 Jul-Aug;5(4):399–403. doi: 10.1161/01.hyp.5.4.399. [DOI] [PubMed] [Google Scholar]
  5. Gallagher G., Jr, Lavanchy P. G., Webster C. A., Wilson J. W., Hieble J. P., DeMarinis R. M. 4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist. J Med Chem. 1985 Oct;28(10):1533–1536. doi: 10.1021/jm00148a028. [DOI] [PubMed] [Google Scholar]
  6. Heykants J., Hendriks R., Meuldermans W., Michiels M., Scheygrond H., Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70. doi: 10.1007/BF03189516. [DOI] [PubMed] [Google Scholar]
  7. Hjemdahl P. Plasma catecholamines as markers for sympatho-adrenal activity in human primary hypertension. Pharmacol Toxicol. 1988;63 (Suppl 1):27–31. doi: 10.1111/j.1600-0773.1988.tb02034.x. [DOI] [PubMed] [Google Scholar]
  8. Ho K. Y., Thorner M. O. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs. 1988 Jul;36(1):67–82. doi: 10.2165/00003495-198836010-00005. [DOI] [PubMed] [Google Scholar]
  9. Kalsner S., Chan C. C. Inhibition by dopamine of the stimulation-induced efflux of [3H]noradrenaline in renal arteries: limitations of the unitary hypothesis of presynaptic regulation of transmitter release. Can J Physiol Pharmacol. 1980 May;58(5):504–512. doi: 10.1139/y80-084. [DOI] [PubMed] [Google Scholar]
  10. Kohli J. D., Glock D., Goldberg L. I. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol. 1983 Apr 22;89(1-2):137–141. doi: 10.1016/0014-2999(83)90618-0. [DOI] [PubMed] [Google Scholar]
  11. Kolloch R., Kobayashi K., DeQuattro V. Dopaminergic control of sympathetic tone and blood pressure: evidence in primary hypertension. Hypertension. 1980 Jul-Aug;2(4):390–394. doi: 10.1161/01.hyp.2.4.390. [DOI] [PubMed] [Google Scholar]
  12. Laduron P. M., Leysen J. E. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979 Jul 15;28(14):2161–2165. doi: 10.1016/0006-2952(79)90198-9. [DOI] [PubMed] [Google Scholar]
  13. Lemberger L., Crabtree R. E. Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science. 1979 Sep 14;205(4411):1151–1153. doi: 10.1126/science.382359. [DOI] [PubMed] [Google Scholar]
  14. Lokhandwala M. F., Jandhyala B. S. The role of sympathetic nervous system in the vascular actions of dopamine. J Pharmacol Exp Ther. 1979 Jul;210(1):120–126. [PubMed] [Google Scholar]
  15. Meineke I., Stüwe E., Henne E. M., Rusteberg G., Brendel E., De Mey C. Routine measurement of plasma catecholamines in clinical pharmacology by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1989 Sep 1;493(2):287–303. doi: 10.1016/s0378-4347(00)82735-8. [DOI] [PubMed] [Google Scholar]
  16. Mohanty P. K., Sowers J. R., Beck F. W., Godschalk M. F., Schmitt J., Newton M., McNamara C., Verbalis J. G., McClanahan M. Catecholamine, renin, aldosterone, and arginine vasopressin responses to lower body negative pressure and tilt in normal humans: effects of bromocriptine. J Cardiovasc Pharmacol. 1985 Nov-Dec;7(6):1040–1047. doi: 10.1097/00005344-198511000-00005. [DOI] [PubMed] [Google Scholar]
  17. Niemegeers C. J., Schellekens K. H., Janssen P. A. The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther. 1980 Mar;244(1):130–140. [PubMed] [Google Scholar]
  18. Pollak P., Gaio J. M., Chateau R. Prévention par le dompéridone de l'hypotension artérielle induite par la bromocriptine. Nouv Presse Med. 1981 Oct 31;10(39):3245–3245. [PubMed] [Google Scholar]
  19. Quinn N., Illas A., Lhermitte F., Agid Y. Bromocriptine in Parkinson's disease: a study of cardiovascular effects. J Neurol Neurosurg Psychiatry. 1981 May;44(5):426–429. doi: 10.1136/jnnp.44.5.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rinne U. K. Role of dopamine receptors in neurological drug treatment. Ann Clin Res. 1988;20(5):334–339. [PubMed] [Google Scholar]
  21. Sowers J. R., Golub M. S., Berger M. E., Whitfield L. A. Dopaminergic modulation of pressor and hormonal responses in essential hypertension. Hypertension. 1982 May-Jun;4(3):424–430. doi: 10.1161/01.hyp.4.3.424. [DOI] [PubMed] [Google Scholar]
  22. Whitfield L., Sowers J. R., Tuck M. L., Golub M. S. Dopaminergic control of plasma catecholamine and aldosterone responses to acute stimuli in normal man. J Clin Endocrinol Metab. 1980 Oct;51(4):724–729. doi: 10.1210/jcem-51-4-724. [DOI] [PubMed] [Google Scholar]
  23. de Mey C., Enterling D., Meineke I., Brendel E. Effects of the novel D2-dopaminergic agonist ropinirol on supine resting and stimulated circulatory and neuroendocrine variables in healthy volunteers. Arzneimittelforschung. 1990 Jan;40(1):7–13. [PubMed] [Google Scholar]
  24. de Mey C., Enterling D. Variant responses impair the usefulness of passive upright tilt in drug research. Methods Find Exp Clin Pharmacol. 1988 Jan;10(1):57–64. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES